More than ever, small and medium-sized biopharma companies are driving change in the pharmaceutical industry. In the past, they served mainly as a source of scientific innovation feeding into the acquisition pipelines of big pharma.
This is changing massively with new ways of commercialization and the trend to more specialized treatment options for smaller patient populations. The requirements of emerging biopharma companies differ significantly from those of big pharma—they are more agile, less resourced, and less siloed when it comes to collaboration and knowledge sharing. This has a direct impact on which agency partner is the right choice to aid in the pre-launch or launch phase of development.
Read this article to find out what biopharma companies should look for when choosing an agency partner.